# Santhera Pharmaceuticals clinical trials: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials with Santhera Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Santhera Pharmaceuticals: 27 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/santhera-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 3, 2024 | NCT06713135 | A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy | Santhera Pharmaceuticals | Phase 4 | Active not recruiting | Duchenne Muscular Dystrophy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06713135) |
| November 14, 2024 | NCT06689527 | Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics | Santhera Pharmaceuticals | Phase 1 | Completed | Drug Interaction | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06689527) |
| October 18, 2024 | NCT06649409 | Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects | Santhera Pharmaceuticals | Phase 1 | Completed | Pharmacodynamic | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06649409) |
| January 11, 2022 | NCT05185622 | A Study to Assess Vamorolone in Boys Ages 2 to \<4 Years and 7 to \<18 Years With Duchenne Muscular Dystrophy (DMD) | Santhera Pharmaceuticals | Phase 2 | Completed | Duchenne Muscular Dystrophy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05185622) |
| May 8, 2020 | NCT04381091 | Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study | Santhera Pharmaceuticals | Not applicable | No longer available | Leber's Hereditary Optic Neuropathy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04381091) |
| March 5, 2019 | NCT03863119 | Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy | Santhera Pharmaceuticals | Not applicable | Available | Duchenne Muscular Dystrophy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03863119) |
| November 20, 2018 | NCT03748199 | Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF | Santhera Pharmaceuticals | Phase 1/2 | Completed | Cystic Fibrosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03748199) |
| July 27, 2018 | NCT03603288 | Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E) | Santhera Pharmaceuticals | Phase 3 | Terminated | Duchenne Muscular Dystrophy | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03603288) |
| February 15, 2018 | NCT03433807 | Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD) | Santhera Pharmaceuticals | Not applicable | No longer available | Duchenne Muscular Dystrophy | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03433807) |
| September 2, 2016 | NCT02887443 | A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate | Santhera Pharmaceuticals | Phase 1 | Completed | Drug-Drug Interaction | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02887443) |
| June 27, 2016 | NCT02814019 | A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids | Santhera Pharmaceuticals | Phase 3 | Terminated | Duchenne Muscular Dystrophy (DMD) | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02814019) |
| June 10, 2016 | NCT02796274 | Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON) | Santhera Pharmaceuticals | Observational | Completed | Leber's Hereditary Optic Neuropathy (LHON) | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02796274) |
| May 16, 2016 | NCT02774005 | Study to Assess the Efficacy and Safety of Raxone in LHON Patients | Santhera Pharmaceuticals | Phase 4 | Completed | Leber's Hereditary Optic Neuropathy (LHON) | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02774005) |
| May 13, 2016 | NCT02771379 | Post Authorisation Safety Study With Raxone in LHON Patients | Santhera Pharmaceuticals | Observational | Completed | Leber's Hereditary Optic Neuropathy (LHON) | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02771379) |
| July 8, 2013 | NCT01892943 | Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey | Santhera Pharmaceuticals | Observational | Completed | Leber Hereditary Optic Neuropathy (LHON) | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01892943) |
| March 5, 2013 | NCT01805024 | Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and... | Santhera Pharmaceuticals | Phase 1 | Completed | Congenital Muscular Dystrophy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01805024) |
| December 20, 2011 | NCT01495715 | Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) | Santhera Pharmaceuticals | Phase 3 | Withdrawn | Leber's Hereditary Optic Neuropathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01495715) |
| August 22, 2011 | NCT01421381 | RHODOS Follow-up Single-visit Study | Santhera Pharmaceuticals | Observational | Completed | Leber's Hereditary Optic Neuropathy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01421381) |
| February 24, 2011 | NCT01303406 | Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) | Santhera Pharmaceuticals | Phase 3 | Completed | Friedreich's Ataxia | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01303406) |
| December 9, 2009 | NCT01027884 | Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) | Santhera Pharmaceuticals | Phase 3 | Completed | Muscular Dystrophy, Duchenne, Ambulatory Care | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01027884) |
| October 14, 2009 | NCT00993967 | Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) | Santhera Pharmaceuticals | Phase 3 | Completed | Freidreich's Ataxia | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00993967) |
| May 20, 2009 | NCT00905268 | A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients | Santhera Pharmaceuticals | Phase 3 | Completed | Friedreich's Ataxia | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00905268) |
| September 25, 2008 | NCT00758225 | Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension) | Santhera Pharmaceuticals | Phase 2 | Completed | Duchenne Muscular Dystrophy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00758225) |
| September 5, 2008 | NCT00747487 | Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy | Santhera Pharmaceuticals | Phase 2 | Completed | Leber's Hereditary Optic Neuropathy | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00747487) |
| June 13, 2008 | NCT00697073 | Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients | Santhera Pharmaceuticals | Phase 3 | Completed | Friedreich's Ataxia | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00697073) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 9 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| No longer available | 2 |
| Terminated | 2 |
| Withdrawn | 1 |
| Available | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Muscular Dystrophy, Duchenne | 9 |
| Optic Atrophy, Hereditary, Leber | 8 |
| Friedreich Ataxia | 4 |
| Respiratory Aspiration | 1 |
| Cystic Fibrosis | 1 |
| Muscular Dystrophies | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Primary care clinics in the United States](https://specstream.ai/data/businesses/primary-care-clinics/united-states)
- [Roofing contractors in the United States](https://specstream.ai/data/businesses/roofing-contractors/united-states)
